Menu
SOPHiA GENETICS™ is excited to join the European Congress of Pathology annual meeting, held in person in Dublin, Ireland. Join us at booth #59 from September 10-12 to have the chance to chat with our experts and demo the universal SOPHiA DDM™ Platform.
Mark your agenda on September 11th at 07:15am in room Wicklow Hall 1 for our satellite symposium:
“Unlocking Precision Oncology Insights with Decentralized NGS Data Analysis”
Next-generation sequencing (NGS) has significantly advanced precision oncology approaches by enabling clinicians and researchers to accurately characterize tumor molecular profiles. However, following complex workflows and analyzing large NGS datasets can impact the time to results.
During this symposium, our expert speakers will present their experience with the analytics of the SOPHiA DDM™ Platform applied on real-world cases. In particular, you will learn how the platform can detect complex variants and help you uncover insights and inform data-driven decisions across cancer types.
Decentralizing collective intelligence in precision oncology
Dr. Alex Tuck, SOPHiA GENETICS, Switzerland
Analytical performance of CNV calling prototype for Homologous Recombination Deficiency (HRD) detection
Dr. Maria De Bonis, Health Care Executive, UOS di Diagnostica Molecolare e Genomica, Policlinico Gemelli, Italy
The impact of NGS molecular profiling in Chronic Lymphocytic Leukemia (CLL)
Dr. Dolors Colomer, Senior Consultant, Chief Hematopathology Section, Hospital Clínic Barcelona, Spain
Meet us also on September 11th at 1:00pm at booth #59 to discuss with our experts and industry speakers how the SOPHiA DDM™ Platform can help you – refreshments served.
Add to Calendar
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us at [email protected] to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.
